scholarly journals ZINC SUPPLEMENTATION FOR RESPIRATORY ILLNESS AND ACUTE GASTROENTERITIS AS COMPLEMENT TREATMENT FOR COVID-19

2020 ◽  
Vol 4 (6) ◽  
Author(s):  
Chandrika Murugaiah
Keyword(s):  
Clinical Trials ◽  
Acute Gastroenteritis ◽  
Potential Role ◽  
Zinc Supplementation ◽  
Respiratory Illness ◽  
Atypical Pneumonia ◽  
The Novel ◽  
Duration Of Hospitalization ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness

An outbreak of atypical pneumonia by the novel coronavirus disease 2019 (COVID-19), has been reported in Wuhan, China since December, 2019. It is a severe respiratory illness with many other symptoms such as gastroenteritis. Clinical trials has proved that  Zn is a promising supplement that can ease of cough, fever and vomiting, dysentery, respiratory illness, diarrhea duration and recovery, duration of hospitalization and morbidity. This article suggests a potential role, which should be considered in the clinical management, and safeness for Zn supplementation for respiratory illness and acute gastroenteritis as compliment treatment for covid-19.

scholarly journals A comprehensive review on epidemiology, aetiopathogenesis, diagnosis and treatment of the novel coronavirus syndrome – COVID-19

2020 ◽  
Vol 2 (2) ◽  
pp. 110-123
Author(s):  
Kulvinder Kochar Kaur ◽  
◽  
Gautam Allahbadia ◽  
Mandeep Singh ◽  
◽  
...  
Keyword(s):  
Respiratory Illness ◽  
World Health ◽  
The Novel ◽  
Rt Pcr ◽  
Chain Reaction ◽  
Rapid Spread ◽  
Polymerase Chain ◽  
Novel Coronavirus ◽  
Health Organization ◽  
Severe Respiratory Illness

Since the outbreak of the novel Coronavirus in December 2019 in Wuhan China, this novel Coronavirus disease(COVID-19) has spread worldwide taking not only epidemic proportions but with its rapid spread world health organization(WHO) was forced to declare it as a pandemic. The Severe Acute respiratory syndrome (SARS)-Coronavirus (CoV2) virus is responsible for clusters of severe respiratory illness that simulates acute respiratory syndrome that was what was initially. It is thought although that it is equivalent to the high altitude pulmonary oedema (HAPE), showing glass ground opacities in lungs. More experience is getting acquired with changes in treatment approaches from PEEP to avoid intubation and just ensure oxygen levels maintained. Human to human transmission through droplets, contaminated hands as well as surfaces, has been revealed with an incubation period varying from 2-14 days. Early diagnosis using reverse transcription polymerase chain reaction (RT-PCR) or computed tomography (CT) scan chest, quarantine, as well as supportive treatment are necessary for getting a cure. In this review we have tried to analyze the epidemiology, diagnosis, isolation, and treatment, including antiviral drugs like remdesivir, favipiravir, chloroquine and hydroxychloroquine, corticosteroids, antibiotics, and ivermectin. With 3 successful cases of convalescent plasma achieved in USA, trials going on in India along with vaccines are also detailed in this article.

scholarly journals COVID-19 pandemic: The deadly respiratory disease of 21st century

2021 ◽  
Vol 11 (1) ◽  
pp. 01-18
Author(s):  
Shweta Jain ◽  
◽  
Pankaj Kumar Jain ◽  
Ramakant Yadav ◽  
Surendra Kumar Jain ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Respiratory Disease ◽  
Clinical Investigation ◽  
Respiratory Illness ◽  
The Novel ◽  
Major Threat ◽  
The World ◽  
Prevention And Treatment ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness

The sudden outbreak of 2019 novel coronavirus (2019-nCoV) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originated from Wuhan, China. SARS-CoV-2 causes severe respiratory illness and becomes a major threat for humanity. Recently the entire scientist, researchers and physicians all over the countries focused to find the treatment of this pandemic disease. Numerous drugs and or vaccines have been trialed for prevention and treatment against 2019-nCoV but no therapy has been shown effective to date. Currently, numerous vaccines are under clinical investigation and mRNA-1273 vaccine (LNP- encapsulated mRNA vaccine encoding S protein) from Moderna is ahead. Although chloroquine, hydroxychloroquine, remdesivir and many other drugs had recommended against SARS-CoV-2, but still they are not the guarantee treatment of COVID-19. Recently, India, America, Russia and China introduced vaccines against COVID-19 in the market, however assurance of their 100% effectiveness are doubtful. The speed of daily new cases threatens the world and urges the scientist to crack this pandemic condition. KEYWORDS: 2019-nCoV; Chloroquine; COVID-19; Moderna; Respiratory disease; Remdesivir.

scholarly journals The United Kingdom public health response to an imported laboratory confirmed case of a novel coronavirus in September 2012

2012 ◽  
Vol 17 (40) ◽  
Author(s):  
R G Pebody ◽  
M A Chand ◽  
H L Thomas ◽  
H K Green ◽  
N L Boddington ◽  
...  
Keyword(s):  
Severe Disease ◽  
Fatal Case ◽  
Respiratory Illness ◽  
The Novel ◽  
Public Health Response ◽  
The United Kingdom ◽  
Health Response ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness ◽  
Close Contacts

On 22 September 2012, a novel coronavirus, very closely related to that from a fatal case in Saudi Arabia three months previously, was detected in a previously well adult transferred to intensive care in London from Qatar with severe respiratory illness. Strict respiratory isolation was instituted. Ten days after last exposure, none of 64 close contacts had developed severe disease, with 13 of 64 reporting mild respiratory symptoms. The novel coronavirus was not detected in 10 of 10 symptomatic contacts tested.

scholarly journals Dysregulation of RNA interference components in COVID-19 patients

2021 ◽  
Vol 14 (1) ◽  
Author(s):  
Seyyed Reza Mousavi ◽  
Maryam Sadat Sajjadi ◽  
Farinaz Khosravian ◽  
Sara Feizbakhshan ◽  
Sharareh Salmanizadeh ◽  
...  
Keyword(s):  
Rna Interference ◽  
Defense Mechanisms ◽  
Respiratory Illness ◽  
Transcriptional Gene Silencing ◽  
The Novel ◽  
Wuhan City ◽  
Post Transcriptional Gene Silencing ◽  
Essential Components ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness

Abstract Objective Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the novel coronavirus causing severe respiratory illness (COVID-19). This virus was initially identified in Wuhan city, a populated area of the Hubei province in China, and still remains one of the major global health challenges. RNA interference (RNAi) is a mechanism of post-transcriptional gene silencing that plays a crucial role in innate viral defense mechanisms by inhibiting the virus replication as well as expression of various viral proteins. Dicer, Drosha, Ago2, and DGCR8 are essential components of the RNAi system, which is supposed to be dysregulated in COVID-19 patients. This study aimed to assess the expression level of the mentioned mRNAs in COVID-19patients compared to healthy individuals. Results Our findings demonstrated that the expression of Dicer, Drosha, and Ago2 was statistically altered in COVID-19 patients compared to healthy subjects. Ultimately, the RNA interference mechanism as a crucial antiviral defense system was suggested to be dysregulated in COVID-19 patients.

scholarly journals Atypical respiratory distress in eastern Democratic Republic of the Congo prior to the COVID-19 pandemic. A case report

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Guy-Quesney Mateso ◽  
Marius Baguma ◽  
Pacifique Mwene-Batu ◽  
Ghislain Maheshe Balemba ◽  
Fabrice Nzabara ◽  
...  
Keyword(s):  
Respiratory Distress ◽  
Democratic Republic ◽  
Atypical Pneumonia ◽  
The Novel ◽  
Republic Of The Congo ◽  
Chest X Ray ◽  
Novel Coronavirus ◽  
Laboratory Changes ◽  
Official Declaration ◽  
Ray Series

Abstract Background Predictions have been made that Africa would be the most vulnerable continent to the novel Coronavirus disease 2019 (COVID-19). Interestingly, the spread of the disease in Africa seems to have been delayed and initially slower than in many parts of the world. Here we report on two cases of respiratory distress in our region before the official declaration of the disease in December 2019, cases which in the present times would be suspect of COVID-19. Case presentation These two cases (one 55-year-old man and one 25-year-old woman) of acute respiratory distress secondary to atypical pneumonia were seen in Bukavu, in Eastern Democratic Republic of the Congo (DRC), between September and December 2019. One patient had returned from China and the other had close contacts with travellers from China in the 2 weeks prior to the onset of symptoms. In either case, the aetiology could not be accurately determined. However, the two cases presented a clinical picture (progressive dyspnoea, preceded by dry cough and fever) and laboratory changes (procalcitonin within the normal range, slight inflammation, and lymphopenia) compatible with a viral infection. The chest X-ray series of the first patient showed lesions (reticulations, ground glass, and nodules ≤6 mm) similar to those currently found in COVID-19 patients. In addition, unlike the 25-year-old female patient who had no comorbidity, the 55-year-old male patient who had hypertension as comorbidity, developed a more severe acute respiratory distress which progressed to death. Conclusion These cases bring to the attention the fact that COVID-19-like syndromes may have already been present in the region months before the official beginning of the pandemic. This also brings to question whether a prior presence of the disease or infections with related virus may account for the delayed and less extensive development of the pandemic in the region.

scholarly journals Covid-19 and food security: Jeopardy management and posterity deliberations

2021 ◽  
Vol 10 (2) ◽  
pp. 01-05
Author(s):  
Augustine Owusu-Addo ◽  
Atianashie Miracle A ◽  
Chukwuma Chinaza Adaobi ◽  
Larissa Agbemelo-Tsomafo
Keyword(s):  
Food Processing ◽  
Respiratory Illness ◽  
The United States ◽  
The Novel ◽  
Food Handling ◽  
Global Pandemic ◽  
Food Borne ◽  
Novel Coronavirus ◽  
Food Borne Infections ◽  
Safety Guidelines

COVID-19, also known as the ‘novel coronavirus disease 2019’, is a respiratory illness and the causative pathogen is officially named as ‘SARS-CoV-2’. Infections with SARS-CoV-2 have now been amplified to a global pandemic – as of April 3, 2020, nearly 1,018,000 cases have been confirmed in more than 195 countries, including more than 300,000 cases within the United States. Public safety guidelines are followed worldwide to stop the spread of COVID-19 and stay healthy. Despite COVID-19 is a respiratory illness with mode of invasion through the respiratory tract, not the gastrointestinal tract, an average food consumer is anxious and concerned about the food safety. Could an individual catch the deadly contagious COVID-19 from groceries brought home from the supermarket – or from the next restaurant takeout order? This brief review elucidates the epidemiology and pathobiological mechanism(s) of SARS-CoV-2 and its implications in food-borne infections, transmission via food surfaces, food processing and food handling.

scholarly journals POTENTIAL THERAPIES FOR TREATMENT OF COVID-19

2020 ◽  
Vol 7 (1) ◽  
pp. 062-071
Author(s):  
Beatriz Gasser ◽  
Ricardo Andres Ramirez Uscategui
Keyword(s):  
Clinical Trials ◽  
Distress Syndrome ◽  
Multiple Organ ◽  
The Novel ◽  
Controlled Clinical Trials ◽  
Interferon Β ◽  
The World ◽  
Novel Coronavirus ◽  
Time Point

Since discovery of the novel coronavirus (SARS-CoV-2) in December of 2019, this viral pneumonia originated in Wuhan, China quickly spread around the world. This new disease, called COVID-19 can cause Acute Respiratory Distress Syndrome (ARDS) due to an uncontrolled inflammatory response like sepsis, that leads to multiple organ failure and even death. Several pharmacotherapeutics alternatives are being tested over the world, looking for most diverse drugs that might be able to fight the infection. The objective of this paper is to review the main pharmacotherapeutics techniques development, as remdesivir, chloroquine/hydroxychloroquine, lopinavir plus ritonavir, interferon-β, ivermectin, anticoagulants, convalescent plasma and vaccine, currently undergoing clinical trials in order to evaluate its effectiveness and safety to combat the COVID-19, presenting their characteristics, possible adverse effects and main scientific findings of its potential action. In conclusion, some therapies presented promising in-vitro results or in the treatment of some patients, nonetheless, multicentric blinded placebo controlled clinical trials are necessary to determine their effectiveness, safety, dosage, and best time point of treatment.

scholarly journals Vitamin C Symposium 2019—“Vitamin C for Cancer and Infection: From Bench to Bedside”

Proceedings ◽  
2019 ◽  
Vol 5 (1) ◽  
pp. 3
Author(s):  
Anitra Carr
Keyword(s):  
Clinical Trials ◽  
Vitamin C ◽  
Clinical Outcomes ◽  
Respiratory Illness ◽  
Severe Respiratory Illness

The Vitamin C for Cancer and Infection symposium was organised in response to recent international clinical trials that have highlighted the potential for vitamin C administration to improve clinical outcomes for patients with severe respiratory illness, sepsis and some cancers [...]

scholarly journals SARS-CoV-2, ACE2 expression, and systemic organ invasion

2020 ◽  
Author(s):  
Usman M Ashraf ◽  
Ahmed A Abokor ◽  
Jonnelle M. Edwards ◽  
Emily W. Waigi ◽  
Rachel S. Royfman ◽  
...  
Keyword(s):  
Respiratory Illness ◽  
Normal Function ◽  
Multiple Organ ◽  
Angiotensin Converting Enzyme 2 ◽  
Multiple Organs ◽  
Global Pandemic ◽  
Organ Systems ◽  
Novel Coronavirus ◽  
Severe Respiratory Illness ◽  
Organ Invasion

A novel coronavirus disease, COVID-19, has created a global pandemic in 2020, posing an enormous challenge to healthcare systems and affected communities. COVID-19 is caused by Severe Acute Respiratory Syndrome (SARS)-CoronaVirus-2 (CoV-2) that manifests as bronchitis, pneumonia, or a severe respiratory illness. SARS-CoV-2 infects human cells via binding a "spike" protein on its surface to angiotensin-converting enzyme 2 (ACE2) within the host. ACE2 is crucial for maintaining tissue homeostasis and negatively regulates the renin-angiotensin-aldosterone system (RAAS) in the humans. The RAAS is paramount for normal function in multiple organ systems including the lungs, heart, kidney, and vasculature. Given that SARS-CoV-2 internalizes via ACE2, the resultant disruption in ACE2 expression can lead to altered tissue function and exacerbate chronic diseases. The widespread distribution and expression of ACE2 across multiple organs is critical to our understanding of the varied clinical outcomes of COVID-19. This perspective review based on the current literature was prompted to show how disruption of ACE2 by SARS-CoV-2 can affect different organ systems.

Sign in / Sign up

Export Citation Format

Share Document